Overview

• Pfizer will offer most-favored-nation prices to Medicaid and sell a large share of its medicines at discounts through the planned TrumpRx.gov direct-purchase portal.
• The White House fact sheet cites steep cuts for select drugs bought directly, including Eucrisa at 80% off, Xeljanz at 40% off, and Zavzpret at 50% off.
• Pfizer pledged about $70 billion for U.S. research and manufacturing, making it eligible for a likely three-year reprieve from certain pharmaceutical tariffs.
• The administration’s 100% tariff on imported branded drugs is slated to begin Oct. 1 for companies not building U.S. plants, while several manufacturers say negotiations continue past the deadline.
• Experts say the impact on commercially insured patients is unclear, officials indicate many price changes may not be felt until 2026, and analysts warn tariffs could raise costs or disrupt global supply chains.